Showing 1901-1910 of 3038 results for "".
- Prof. John M. Nolan Receives Heidelberg Engineering Xtreme Research Award 2020https://modernod.com/news/prof-john-m-nolan-receives-heidelberg-engineering-xtreme-research-award-2020/2477755/Prof. John M. Nolan, from the Nutrition Research Centre Ireland, School of Health Science, Waterford Institute of Technology (Ireland), is the recipient of the Heidelberg Engineering Xtreme Research Award 2020 for his research related to macular pigment for vision health and function, as well as
- Gilead Inks Non-US Deals With Five Generic Drugmakers to Expand Supply of COVID-19 Drug Remdesivirhttps://modernod.com/news/gilead-inks-non-us-deals-with-five-generic-drugmakers-to-expand-supply-of-covid-19-drug-remdesivir/2477757/Gilead Sciences said it has signed non-exclusive voluntary licensing agreements with Cipla, Ferozsons Laboratories, Hetero Labs, Jubilant Lifesciences and Mylan to manufacture COVID-19 treatment remdesivir for distribution in 127 countries. According to Gilead, the list consists of nearly all low
- Novavax Granted Up to $384 Million in New CEPI Funding for COVID-19 Vaccine Candidatehttps://modernod.com/news/novavax-granted-up-to-384-million-in-new-cepi-funding-for-covid-19-vaccine-candidate/2477747/Novavax announced that the Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $384 million of additional funding, on top of $4 million it invested in March, to advance clinical development of the company’s vaccine candidate NVX-CoV2373 against SARS-CoV-2. In Ap
- Dyno Therapeutics Collaborates With Novartis to Develop Improved Gene Therapies With AAV Vectors Based on AI Technologyhttps://modernod.com/news/dyno-therapeutics-collaborates-with-novartis-to-develop-improved-gene-therapies-with-aav-vectors-based-on-ai-technology/2477740/Dyno Therapeutics announced a collaboration with Novartis to develop improved adeno-associated virus (AAV) vectors for research, development, and commercialization of gene therapies for ocular diseases. Financial terms of the deal were not disclosed. The partnership will allow the p
- Quest, LabCorp Launch Nationwide COVID-19 Antibody Testing in Pharmacies and Onlinehttps://modernod.com/news/quest-labcorp-launch-nationwide-covid-19-antibody-testing-in-pharmacies-and-online/2477677/Weeks after launching their own COVID-19 molecular testing initiatives, lab giants Quest Diagnostics and LabCorp have begun offering antibody tests nationwide for the next phase of the coronavirus pandemic, according to a FierceBiotech
- SightGlass Vision Unveils Topline Data From Study of Novel Eyeglasses Designed to Control Myopia in Childrenhttps://modernod.com/news/sightglass-vision-unveils-topline-data-from-study-of-novel-eyeglasses-designed-to-control-myopia-in-children/2477653/SightGlass Vision announced topline data from the company’s pivotal trial evaluating its novel eyeglasses designed to slow the progression of myopia in children. Results from a planned 12-month interim analysis of the CYPRESS clinical study (NCT03623074) demonstrated a reduction in myopia p
- Q BioMed Initiates Rapid Development of Novel COVID-19 Therapeuticshttps://modernod.com/news/q-biomed-initiates-rapid-development-of-novel-covid-19-therapeutics/2477631/Q BioMed announced that together with its technology partner, Mannin Research, they are accelerating the rapid development of novel drugs for the treatment of life-threatening complications caused by COVID-19 and other viral infections. This novel drug program is being evaluated by government pro
- Novartis Acquires Amblyotech, A Provider of Digital Therapy for Treatment of Amblyopiahttps://modernod.com/news/novartis-acquires-amblyotech-a-provider-of-digital-therapy-for-treatment-of-amblyopia/2477623/Novartis announced that it has completed the acquisition of Amblyotech, a US-based software startup, and will, in collaboration with Ubisoft and McGill University, pursue the development of the acquired digital technology for the treatment of amblyopia. It is estimated that amblyopia affec
- NovaBay Pharmaceuticals Signs Agreement to Distribute COVID-19 Antibody Rapid Point-of-Care Test to US Health Care Professionalshttps://modernod.com/news/novabay-pharmaceuticals-signs-agreement-to-distribute-covid-19-antibody-rapid-point-of-care-test-to-u-s-healthcare-professionals/2477616/NovaBay Pharmaceuticals announced an agreement with Shenzhen Microprofit Biotech to become the exclusive US distributor of a rapid, finger prick test to determine the presence of COVID-19 or a potential indication of antibody immunity to COVID-19, according to a company news release. The fluoreca
- Novartis to Conduct Study of Hydroxychloroquine for Hospitalized Patients With COVID-19 Diseasehttps://modernod.com/news/novartis-to-conduct-study-of-hydroxychloroquine-for-hospitalized-patients-with-covid-19-disease/2477617/Novartis announced Monday that it reached an agreement with the FDA to begin a phase 3 study evaluating the use of hydroxychloroquine for the treatment of hospitalized patients with COVID-19 disease. The trial, which will be conduct